AJMC September 17, 2024
Based on an Avalere Health report, Community Oncology Alliance warns that IRA negotiations could slice down payments needed to administer cancer drugs.
Payments to community oncology practices to administer complex cancer drugs could be sliced by $12 billion through 2032, because the Inflation Reduction Act (IRA) fails to separate these costs from negotiations over the prices of the drugs themselves.
That’s the finding of a new analysis by Avalere Health,1 which was commissioned by the Community Oncology Alliance (COA) to examine how the IRA would affect “add-on” payments under Part B to member practices.
A report released Monday shows the loss of these payments to all physicians could reach $25 billion across both Medicare and commercial plans. Because cancer drugs...
Today's Sponsors
Today's Sponsor